DE69506642T2 - Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen - Google Patents

Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen

Info

Publication number
DE69506642T2
DE69506642T2 DE69506642T DE69506642T DE69506642T2 DE 69506642 T2 DE69506642 T2 DE 69506642T2 DE 69506642 T DE69506642 T DE 69506642T DE 69506642 T DE69506642 T DE 69506642T DE 69506642 T2 DE69506642 T2 DE 69506642T2
Authority
DE
Germany
Prior art keywords
provitamins
fatty acids
pharmaceutical preparations
polyunsaturated fatty
preparations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69506642T
Other languages
English (en)
Other versions
DE69506642D1 (de
Inventor
Tiberio Bruzzese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prospa NV
Original Assignee
Prospa NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prospa NV filed Critical Prospa NV
Publication of DE69506642D1 publication Critical patent/DE69506642D1/de
Application granted granted Critical
Publication of DE69506642T2 publication Critical patent/DE69506642T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69506642T 1994-08-25 1995-08-11 Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen Expired - Fee Related DE69506642T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI941774A IT1274734B (it) 1994-08-25 1994-08-25 Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti

Publications (2)

Publication Number Publication Date
DE69506642D1 DE69506642D1 (de) 1999-01-28
DE69506642T2 true DE69506642T2 (de) 1999-07-22

Family

ID=11369490

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69506642T Expired - Fee Related DE69506642T2 (de) 1994-08-25 1995-08-11 Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen
DE0699437T Pending DE699437T1 (de) 1994-08-25 1995-08-11 Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE0699437T Pending DE699437T1 (de) 1994-08-25 1995-08-11 Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen

Country Status (5)

Country Link
US (1) US5776978A (de)
EP (1) EP0699437B1 (de)
JP (1) JPH08175988A (de)
DE (2) DE69506642T2 (de)
IT (1) IT1274734B (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9401743A (nl) * 1994-10-20 1996-06-03 Prospa Bv Zouten van aminoalcoholen en farmaceutische formuleringen die deze bevatten.
JPH10511355A (ja) * 1994-12-22 1998-11-04 ヘンケル コーポレーション トコフェロールとベータ−カロチンの組成物
FR2761887B1 (fr) * 1997-04-11 1999-06-18 Roland Asmar Medicament visant a la prevention multifactorielle des maladies cardiovasculaires
JP2000159678A (ja) * 1998-11-30 2000-06-13 Nof Corp 皮膚外用剤組成物
DE19855426A1 (de) * 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US6436431B1 (en) 2001-07-02 2002-08-20 Diane Wright Hoffpauer Fortified rice bran food product and method for promoting cardiovascular health
FR2826975B1 (fr) * 2001-07-09 2004-06-04 Bio Merieux Utilisation de lipoproteines oxydees pour obtenir la differenciation de monocytes en cellules dendritiques matures
CA2453823C (en) 2001-07-27 2010-12-21 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
JP2003261456A (ja) * 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
EP1517667A2 (de) * 2002-07-02 2005-03-30 Galileo Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur verringerung der entzündungssymptome und/oder biomarkern bei weiblichen patienten
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
KR20050086954A (ko) * 2003-01-17 2005-08-30 바이탈 헬스 사이언시즈 피티와이 리미티드 항증식성 화합물
EP1587377A2 (de) * 2003-01-31 2005-10-26 The Procter & Gamble Company Mittel zur verbesserung deserscheinungsbilds von säugetier-keratingewebe
US20050123500A1 (en) * 2003-01-31 2005-06-09 The Procter & Gamble Company Means for improving the appearance of mammalian hair and nails
EP1637134A4 (de) * 2003-06-20 2010-01-27 Mochida Pharm Co Ltd Zusammensetzung zur prävention/behandlung von varizen
GB0314624D0 (en) 2003-06-23 2003-07-30 Advanced Bionutrition Europ Lt Inflammatory disease treatment
US7416752B2 (en) 2004-01-06 2008-08-26 Sharp Ingrained Functional Foods, Inc. Method of fortifying seeds with an essential fatty acid, fortified seed and food product
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
AU2005202477B2 (en) 2004-03-03 2005-12-15 Vital Health Sciences Pty Ltd Alkaloid formulations
HU227588B1 (hu) * 2004-12-03 2011-09-28 Sinnex Mueszaki Fejlesztoe Es Tanacsado Kft Többszörösen telítetlen zsírsavak észtereit tartalmazó vírusellenes és immunstimuláns gyógyászati készítmény
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
EP1904049B1 (de) * 2005-07-08 2016-12-07 DSM IP Assets B.V. Mehrfach ungesättigte fettsäuren zur behandlung von demenz und prä-demenz-erkrankungen
ATE510464T1 (de) * 2005-08-26 2011-06-15 Nestec Sa ZUSAMMENSETZUNGEN UND VERFAHREN ZUR VERBESSERUNG DER FUNKTIONALEN GEFÄßINTEGRITÄT, DES ÜBERLEBENS DER ZELLEN UND DER REDUCTION DER APOPTOSE NACH EINEM ISCHÄMIEANFALL IM GEHIRN
AU2011221341B2 (en) * 2005-08-26 2013-11-28 Nestec S.A. Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain
CN101247736B (zh) * 2005-08-26 2012-11-07 雀巢技术公司 用于提高功能性血管完整性、细胞存活和在脑中局部缺血或者局部缺血发作后减少程序性细胞死亡的组合物和方法
US20070104779A1 (en) * 2005-11-07 2007-05-10 Rongen Roelof M Treatment with omega-3 fatty acids and products thereof
AU2007271900B2 (en) * 2006-07-14 2013-05-23 Nattopharma As Pharmaceutical and nutraceutical products comprising vitamin K2
EP1897530A1 (de) * 2006-09-08 2008-03-12 DSMIP Assets B.V. Hautpflegezusammensetzung
EP3539560A1 (de) 2007-02-22 2019-09-18 Children's Hospital & Research Center at Oakland Fettsäureformulierungen und verwendungsverfahren dafür
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
PT2334295T (pt) 2008-09-02 2017-09-15 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica compreendendo ácido eicosapentanoico e ácido nicotínico e métodos de utilização dos mesmos
US20100130608A1 (en) * 2008-10-01 2010-05-27 Martek Biosciences Corporation Compositions and methods for reducing triglyceride levels
WO2010055419A2 (en) * 2008-11-14 2010-05-20 Framroze Bomi P A method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
SI2596786T1 (sl) 2009-02-10 2020-03-31 Amarin Pharmaceuticals Ireland Limited, Uporaba etilestra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
MY198422A (en) 2009-04-29 2023-08-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
DK3278665T3 (da) 2009-04-29 2020-11-30 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til anvendelse deraf
US20110196383A1 (en) * 2009-05-05 2011-08-11 Atherolysis Medical, Inc Atherosclerotic Plaque Dissolution Composition
US8455472B2 (en) 2009-06-15 2013-06-04 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
CA3043081C (en) * 2010-03-04 2020-02-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating and/or preventing cardiovascular disease
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
EP3593794A1 (de) 2010-05-26 2020-01-15 Kerecis EHF Stabilisierte zubereitung enthaltend omega-3 fettsäuren und ihre verwendung zur hautpflege und/oder wundversorgung
WO2012032416A2 (en) 2010-09-07 2012-03-15 Ocean Nutrition Canada Limited Comestible emulsions
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CL2010001587A1 (es) * 2010-12-27 2013-01-11 Golden Omega S A Proceso de preparacion de un concentrado de etil esteres de acidos grasos omega-3 que comprende sobre el 80% en peso de dichos esteres en configuracion cis y sus dobles enlaces separados por una unidad metilenica.
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2800469B1 (de) 2012-01-06 2021-08-25 Amarin Pharmaceuticals Ireland Limited Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
US20150004224A1 (en) 2012-01-06 2015-01-01 Omthera Phrmaceuticals, Inc. Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
AU2013259503B2 (en) 2012-05-10 2017-03-16 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
US9603826B2 (en) 2012-06-29 2017-03-28 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
CN103976038A (zh) * 2014-05-16 2014-08-13 普洱联众生物资源开发有限公司 一种具有抗氧化功能的天然植物油
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
WO2016096685A1 (en) * 2014-12-15 2016-06-23 Dsm Ip Assets B.V. Treatment for non-alcoholic fatty liver diseases
CN104855957A (zh) * 2015-04-20 2015-08-26 李燕铭 一种具有抗氧化、延缓衰老的医药保健品
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US20200315970A1 (en) * 2016-05-25 2020-10-08 Evonik Technochemie Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
WO2018112512A1 (en) 2016-12-21 2018-06-28 Phosphagenics Limited Process
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
EP3648748A1 (de) 2017-07-06 2020-05-13 Evonik Operations GmbH Enterische beschichtete feste darreichungsform mit omega-3-fettsäure-aminosäure-salzen
AU2018317802B2 (en) 2017-08-15 2024-04-04 Evonik Operations Gmbh Tablets with high active ingredient content of omega-3 fatty acid amino acid salts
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
EP3750536A1 (de) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ireland Limited Verfahren zur verringerung des risikos von kardiovaskulären ereignissen in einem subjekt
EP4009961A1 (de) 2019-08-08 2022-06-15 Evonik Operations GmbH Löslichkeitsverbesserung von schwerlöslichen wirkstoffen
EP4009956A1 (de) 2019-08-08 2022-06-15 Evonik Operations GmbH Down-streaming-vorgang zur herstellung von salzen von mehrfach ungesättigten fettsäuren

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3719097C1 (de) 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5012761A (en) * 1988-11-17 1991-05-07 Oh Suk Y Chicken egg having relatively high percentage of long chain fatty acids and method of reducing heart related disease in humans using such eggs

Also Published As

Publication number Publication date
ITMI941774A1 (it) 1996-02-25
US5776978A (en) 1998-07-07
DE69506642D1 (de) 1999-01-28
EP0699437A1 (de) 1996-03-06
IT1274734B (it) 1997-07-24
EP0699437B1 (de) 1998-12-16
DE699437T1 (de) 1996-11-07
JPH08175988A (ja) 1996-07-09
ITMI941774A0 (it) 1994-08-25

Similar Documents

Publication Publication Date Title
DE69506642T2 (de) Pharmazeutische Zubereitungen enthaltend mehrfach ungesättigte Fettsäuren zusammen mit antioxydativen Vitaminen und Provitaminen
DE69328492T2 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
ZA958762B (en) Medicinal and/or nutritional microcapsules for oral administration
EP0675103A3 (de) Derivaten von essentiellen Fettsäuren und nicht-steroidischen entzündungshemmenden Mitteln.
AU2738497A (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
IL122249A0 (en) Fluorocarbon pharmaceutical formulations and their preparation
DE69627817D1 (de) Pharmazeutische zubereitung, die fenofibrat und polyglykolisierte glyceride enthält
KR970012150U (ko) 의약 및 식품용 하드 공 캅셀
IT8721453A0 (it) Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche.
DE69409969T2 (de) Salze der mehrfach ungesättigten fettsäuren und diese enthaltende pharmazeutischen zusammensetzungen
NZ288997A (en) Controlled release pharmaceutical formulation comprising polypeptide encapsulated in alginate
AU4846690A (en) Polyunsaturated fatty acid derivatives, pharmaceutical compositions containing the same, method for the preparation thereof, and their use as medicament
ATE186541T1 (de) Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung
AU2111095A (en) Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them
EE03015B1 (et) Ravimpreparaat ja selle valmistamise protsess
DE69430580D1 (de) Arzneimittel in nahrungsmittelform
DE59604457D1 (de) Zuckertenside und Fettsäurepartialglyceride enthaltende kosmetische und/oder pharmazeutische Zubereitungen
DE69427551T2 (de) Nalbuphinester und diese enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
ZA822933B (en) Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation
AU6083686A (en) Emulsion comprising lipid, non-lipid liquid and pharmaceutical ingredients
IL85776A0 (en) Pharmaceutical compositions comprising certain algae and polyunsaturated fatty acids and their preparation
ITMI920349A0 (it) Agente per la nutrizione dei capelli e sua preparazione
IL120637A0 (en) Retinoids their preparation and pharmaceutical compositions containing them
PT75762A (en) Aminocyclopentane acids and esters and their preparation and pharmaceutical formulation
DE69532578D1 (de) NEUARTIGE GnRH - ANALOGE MIT ANTITUMORALEN EFFEKTEN UND SIE ENTHALTENDE PHARMAZEUTISCHE ZUBEREITUNGEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee